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Background: Ibuprofen and paracetamol are the only antipyretics recommended in
febrile children. According to international guidelines the choice of the drug should rely
on the child’s individual characteristics, while a controversial issue regards the combined
or alternate use of the two drugs.
Objective: To compare the efficacy and safety of combined or alternating use of
ibuprofen and paracetamol in children.
Methods: A systematic review of literature was performed on Medline and Embase
databases. The included studies were randomized controlled trials analyzing the efficacy
of combined or alternating therapy with antipyretics in febrile children vs. monotherapy. A
meta-analysis was performed to measure the effect of treatment on child’s temperature
and discomfort. Adverse effects were analyzed as secondary outcome.
Results: Nine studies were included, involving 2,026 children. Mean temperature was
lower in the combined therapy group at 1 h (mean difference: −0.29◦C; 95%CI: −0.45
to −0.13) after the initial administration of therapy. No statistical difference was found in
mean temperature at 4 and 6 h from baseline. A significant difference was found in the
proportion of children reaching apyrexia at 4 and 6 h with the combined treatment (RR:
0.18, 95%CI: 0.06 to 0.53, and 0.10, 95%CI: 0.01–0.71, respectively) and at 6 h with
alternating treatment (RR: 0.30, 95% CI: 0.15–0.57), compared to children treated with
monotherapy. The child’s discomfort score was slightly lower with alternating therapy vs.
monotherapy. The pooled mean difference in the number of medication doses per child
used during the first 24 h was not significantly different among groups.
Discussion: Combined or alternating therapy resulted more effective than monotherapy
in reducing body temperature. However, the benefit appeared modest and probably not
clinically relevant. The effect on child discomfort and number of doses of medication
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was modest as well. According to our findings, evidences are not robust enough to
encourage combined or alternating paracetamol and ibuprofen instead of monotherapy
to treat febrile children, reinforcing the current recommendation of most of the
international guidelines.
Keywords: children, antipyretics, fever, ibuprofen, paracetamol, acetaminophen
INTRODUCTION
Fever is a physiologic host defense mechanism to infections.
It is one of the most common symptoms in children and
it is usually associated with a self-limiting viral infection (1).
However, it leads to frequent concerns for parents and caregivers,
which may result in “fever phobia,” over-treatment and incorrect
management of the febrile child (2–5). Most experts support the
use of antipyretics in febrile children with the main purpose
to alleviate the child’s discomfort, when present, rather than to
achieve normothermia (6).
Ibuprofen and paracetamol are the only antipyretics
recommended in febrile children, basing on abundant
evidence of their efficacy and safety profile. A recent systematic
literature review (7), including eight studies on 1,632 children,
concluded that both drugs are equally effective in reducing
fever and discomfort in children. Other literature reports,
including two meta-analyses (8, 9), observed a similar safety
profile (10). In a meta-analysis of 19 studies, no significant
difference was observed between the two drugs in the
incidence of adverse events in febrile children (0.82; 95%
CI 0.60–1.12) (9).
According to guidelines recommendations, the choice of the
drug should rely on the child’s individual characteristics, such as
age, underlying clinical conditions, co-medications (11).
A controversial issue regards the combined or alternate
use of the two drugs. Combined therapy is defined as the
simultaneous administration of the two drugs, while alternating
therapy is the administration of both drugs at different time
points. Epidemiological studies reported that these practices
are widespread among pediatricians, nurses, pharmacists, and
caregivers, in different countries. In a recent Italian survey,
12% of 800 interviewed pediatricians declared combined or
alternating prescription habit (12). Higher proportions have been
reported in Switzerland (65%), USA (50%), Turkey (91%), and
Spain (69%) (13–15).
However, there is uncertainty about whether
combined/alternate therapy is superior to the single drug
therapy, especially in terms of discomfort reduction and about
adverse effect profile. Potential renal and liver toxicity caused
by the additive effects of drug metabolites in children has been
suggested. Moreover, some authors underlined the possibility
that caregivers will either not receive or not understand dosing
instructions, increasing the potential for inaccurate dosing or
overdosing. Finally, it has been argued that the combination
strategy is mainly driven by the healthcare professionals’ and
caregivers’ fever phobia and it could be limited with targeted
educational interventions (16, 17).
According to a French cross-sectional observational study
(18), combination treatment was associated with: parents’
profession being a farmer, possibly related to the difficulty in
implementing recommendations in rural areas; a diagnosis of
particularly painful (otitis, pharyngitis) and feverish diseases
(influenza); child’s temperature major than 39◦C, probably due
to the persistence of fever phobia. Furthermore, the study
revealed that parents’ knowledge and practices in managing fever
symptoms frequently differ from recommendations (18, 19).
The rational for the combined or alternate use of ibuprofen
and paracetamol is that a synergism between the two drugs is
plausible, given their different mechanisms of action (17). The
combination of paracetamol and ibuprofen has been found to
be effective in a variety of acute pain states, including post-
operative pain, dysmenorrhea, musculoskeletal pain, and tooth
removal associated pain (17). This is particularly important
considering that discomfort and pain relief is the main objective
of fever treatment. Several clinical trials and systematic reviews
have been published with the aim to explore the effect of
combined/alternate therapy on temperature control and child’s
discomfort, but results are contrasting (20, 21).
A 2013 Cochrane Review of six studies, involving 915
participants, concluded that some evidence exists that combined
or alternate antipyretic therapy may be slightly superior at
reducing temperatures thanmonotherapy. Nonetheless, evidence
for improvements in child’s discomfort, which should be the
primary aim of treatment, were poor. Moreover, the authors
identified concerns regarding the safety of combined and
alternating therapy: even if no serious adverse events were
documented in the trials, no study had sufficient power in terms
of number of participants to make a definitive statement about
frequency of severe adverse effects (22).
Currently the alternate use of two antipyretics is discouraged
by several guidelines with the exception of the UK-NICE (23)
and South Australian CPGs (24). These two guidelines permit
the alternate use only if the discomfort persists or recurs after the
administration of one antipyretic.
On the other hand, the Canadian (25), Italian (11), New
Zealand (26) and South African (27) guidelines discourage this
practice in every case, while the US guidelines (28) state that
there is insufficient evidence to support or refute the routine
use of combined/alternating treatment and “practitioners who
follow this practice should counsel parents carefully regarding
proper formulation, dosing and dosing intervals, and emphasize
the child’s comfort instead of reduction of fever” (29). The current
international guidelines are summarized in Table 1 (30).
Hereby, we perform an updated systematic review and
meta-analysis regarding the efficacy and safety of combined or
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TABLE 1 | Management of fever guidelines (from 29, modified).
Guidelines AAP SIP South- Africa NICE NSW SA WHO CANADA
Country USA Italy South Africa UK New Zealand South Australian Canada
Year 2011 2016 2013 2013 2010 2013 2013 2013
Age of target
population
Not specified 0–18 years Not specified <5 years 1 month−5 years <3 years <5 years Not-specified
SPECIFIC RECOMMENDATIONS
Combination of
paracetamol/ibuprofen
is not recommended
(1) nr nr (3)
Alternating
paracetamol/ibuprofen
is not recommended
(1) (2) (2) nr (3)
Agree.
Disagree.
nr, not reported.
(1) Insufficient evidence to support or refute the routine use of combination treatment.
(2) Alternating the two drugs is possible if the discomfort persists or recurs using only one antipyretic.
(3) Do not alternate between using acetaminophen and ibuprofen as this can lead to dosing errors.
alternate use of antipyretics in children, in order to provide
a state-of-the art summary, 5 year after the 2013 Cochrane
review (22).
MATERIALS AND METHODS
Study Design
A systematic review was performed according to the Cochrane
handbook guidelines (31). The aim of the review was to
assess the efficacy and safety of combined or alternating
use of ibuprofen and paracetamol vs. monotherapy in febrile
children. The included studies were evaluated qualitatively and
quantitatively with a meta-analysis. The PRISMA guideline
recommendations were used to report this systematic review and
meta-analyses (32).
Search Strategy
On September 2018, the MEDLINE and EMBASE databases
were searched.
In MEDLINE the following search strategy was used:
(ibuprofen AND (fever OR pyrexia OR hyperthermia OR
temperature OR febrile OR feverish) AND (infan∗ OR child∗ OR
pediatric∗ OR pediatric∗ OR adolescen∗).
In EMBASE the used search strategy was: “ibuprofen”:ab,ti
AND (“fever”:ab,ti OR “pyrexia”:ab,ti OR “hyperthermia”:ab,ti
OR “temperature”:ab,ti OR “febrile”:ab,ti OR “feverish”:ab,ti)
AND (“infan∗”:ab,ti OR “child∗”:ab,ti OR “pediatric∗”:ab,ti OR
“pediatric∗”:ab,ti OR “adolescen∗”:ab,ti) AND AND (“clinical
trial”/de OR “controlled clinical trial”/de OR “prospective
study”/de OR “randomized controlled trial”/de OR “randomized
controlled trial (topic)”/de).
An additional research was conducted on Google Scholar
and the references of relevant articles were further crosschecked.
No language restriction or publication date restrictions
were applied.
Inclusion Criteria
Studies were considered eligible whether they presented
the following characteristics: (1) study design consisting in
randomized controlled trial (RCT), open or blinded; (2)
population sample represented by children aged 18 or less; (3)
one of the arms of therapy consisting of combined or alternating
antipyretics for fever treatment; (4) available data to measure the
effect of therapy.
Selection of Studies
Titles and abstracts were screened to identify eligible studies.
Then, the full text of all potentially relevant articles was
analyzed for further evaluation. Two investigators (GT and
EC) independently reviewed and evaluated every study.
Disagreements were resolved by consensus.
Data Extraction and Definitions
The following information was extracted: publication
year, country of origin, characteristics of population
sample, diagnostic measures of fever, types of intervention,
outcome measures.
Types of interventions were: combined therapy vs. ibuprofen
or paracetamol alone, alternating therapy vs. ibuprofen or
paracetamol alone, or combined therapy vs. alternating therapy.
The primary outcome measures were: mean temperature
and proportion of febrile children at one, 4 and 6 h after
administration of initial antipyretic, child discomfort evaluated
by stress scores (the Non-communicating Children’s Pain
Checklist, NCCPC) and number of doses of medication given.
The NCCPC score is a validate measure of pain and discomfort
in children who are unable to speak about their pain (33). Adverse
effects of treatments were analyzed as secondary outcome.
Regarding mean reduction in body temperature, there
is no international consensus on the definition of a
clinically significant reduction. Some authors have stated
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that only differences of at least 1◦C could be considered
meaningful (34–36).
Data extraction from the selected articles were carried out
independently by two investigators (GT and EC).
Risk of Bias Assessment
The risk of bias for the studies were assessed using the Cochrane
Risk of Bias tool, which is a domain-based evaluation, consisting
in six domains: sequence generation, allocation concealment,
blinding, missing outcome data, selective outcome reporting, and
other sources of bias. Two other potential sources of bias were
assessed: the potential influence of funding agencies and relevant
disproportions in baseline characteristics among groups (31).
Statistical Analysis
Meta-analyses were performed for studies reporting similar
outcome measures, labeling data by comparisons (combined
therapy vs. single agent, alternating therapy vs. single agent,
combined therapy vs. alternating therapy).
For continuous outcomes, the mean, and standard deviation
of each group were extracted. Then, data were analyzed using
mean differences (MD) and 95% confidence intervals (CI). For
dichotomous outcomes, the number of events and the number of
patients analyzed for each group were extracted. Risk ratio (RR)
was used to report pooled results, with 95% CI.
The magnitude of heterogeneity between studies was
expressed by the I2 index. I2 values of 50% were considered to
represent moderate heterogeneity, I2 values between 50 and 75%
substantial heterogeneity and >75% considerable heterogeneity.
The Chi2 test was also used to evaluate heterogeneity, with a P <
0.1 to represent significant heterogeneity (37).
Estimates of effect were combined using a random-effects
model when moderate heterogeneity existed and a fixed-effect
model when there was no heterogeneity.
Due to the small number of studies included in the meta-
analyses, data were not enough to build funnel plots. Hence,
publication bias was not tested.
The statistical analyses were performed using Review
Manager 5 (38).
Levels of Evidence Assessment
The Grading of Recommendation, Assessment, Development,
and Evaluation (GRADE) Working Group recommendations
(39) were followed to assess the quality of evidence, using the
GRADEpro GDT (Guideline Development Tool) (40).
RESULTS
Literature Screening
The initial search identified 528 records, 393 from MEDLINE
database and 135 from EMBASE database, of which 96 were
duplicates. One additional record was identified using Google
Scholar as search engine. Eleven studies met inclusion criteria
after abstracts and titles were evaluated. Two of these studies were
excluded because data were not reported or not relevant to the
analyses. Nine randomized trial were judged eligible and included
in the analysis. The search results and the selection process are
shown in Figure 1 (34–36).
Study Characteristics
This review included three additional studies (36, 41, 42)
compared to the 2013 Cochrane review. The included studies
were nine RCTs, open or blinded. Patients were a total of 2,026
children, aged 6 months to 14 years, presenting with fever.
Settings were emergency departments, pediatric departments or
outpatient clinics and services.
The majority of studies defined fever as a body temperature
≥38◦C. Only one study considered children with temperature
≥37.8◦C as febrile (43).
For temperature measurement, two studies used axillary
thermometers (41, 43), two studies used tympanometric
thermometers (34, 36), one study used temporal artery
thermometers (44), two studies used rectal thermometers (45,
46), and one study used oral thermometers with children >2
years old and rectal thermometers with children <2 years (47).
One study did not mention the method used to assess body
temperature (42).
In all studies, therapy was administered orally. Seven studies
used paracetamol at dose of 15 mg/kg (34, 36, 42–45, 47), one
study at a dose of 10 mg/kg (41) and one study at a dose of
12.5 mg/kg (46). Seven studies used ibuprofen at a dose of 10
mg/kg (36, 41–45, 47), two studies at a dose of 5 mg/kg (34, 46).
In one study, half of every group received initial loading with
paracetamol [25mg/kg] and the other half received initial loading
with ibuprofen (10 mg/kg) (46).
Four studies compared combined therapy vs. ibuprofen and
paracetamol alone (34, 36, 42, 43), two studies compared
alternating therapy vs. ibuprofen and paracetamol alone (41, 46),
one study compared alternating therapy vs. ibuprofen alone (45),
one study compared alternating therapy vs. paracetamol alone
(47), one study compared combined and alternating therapy vs.
ibuprofen alone and alternating vs. combined therapy (44).
Primary outcome measures included: child’s body
temperature, proportion of children with refractory fever,
scores of child discomfort and amount of antipyretic used at
different time points. Other outcome measures were: time spent
in department, number of emergency department visits, absence
from daycare, recurrence of fever, symptom checklist, parental
perception of efficacy, incidence of adverse effects.
Study characteristics are summarized in Table 2.
Risk of Bias Assessment
The results and summary of risk of bias assessment for included
studies are shown in Figures 2, 3. The majority of included
studies presented low risk of bias. Performance bias (blinding of
participants and personnel) was the dominant cause of high risk
of bias, with two studies (36, 41) presenting high risk, because
not all the investigators were blinded to the intervention, and
one study (46) unclear risk of bias. One study had a high risk
of bias regarding blinding of outcome assessment because all
investigators were un-blinded (41). Selection bias was high in
one study (34), because the authors decided not to report data
on mean temperature at hour 2 and on time spent on the unit.
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FIGURE 1 | Flow chart of study selection.
Effects of Interventions
Analyses were performed for the following comparisons:
alternating therapy vs. single agent, combined therapy vs. single
agent and combined vs. alternating therapy (Tables 3, 4). We
decided to present only the analyses that included additional
studies, compared to the analyses reported in the previous
Cochrane review (22).
Combined Therapy vs. Single Agent
Five studies (34, 36, 42–44) compared therapy with
paracetamol and ibuprofen together at baseline and single
agent therapy. Outcome measures were: proportion of children
remaining febrile and mean temperature at one, 4 and 6 h
from baseline.
No statistical difference was found in the proportion of
children remaining febrile at 1 h after the initial administration
of therapy (RR 0.46, with 95% CI 0.20–1.07, 133 participants,
two trials). Proportion of children remaining febrile after 4 and
6 h from baseline was lower in the combined therapy groups. RR
was 0.18 at 4 h (with 95% CI 0.06–0.53, 289 participants, three
trials) and 0.10 at 6 h (with 95% CI 0.01–0.71, 40 participants,
one trial) (Figure 4).
Mean temperature was lower in the combined therapy group
at 1 h after the initial administration of therapy (MD −0.29,
CI −0.45 to −0.13, 163 participants, two trials). No statistical
difference was found in mean temperature at 4 h (MD −0.12,
CI −0.34 to 0.10, 713 participants, three trials) and 6 h (MD
−0.04, CI −0.13 to 0.05, 580 participants, two trials) from
baseline (Figure 5).
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TABLE 2 | Characteristics of the included studies.
References Country/setting Patients Diagnosis of
fever
Intervention Outcomes
Erlewyn-
Lajeunesse
et al. (34)
UK/single center –
ED
123 children aged 6
months to 10 years
with temperature >
38◦C
tympanometric
thermometer
Group 1: paracetamol 15 mg/kg
single dose Group 2: ibuprofen 5
mg/kg single dose Group 3:
paracetamol 15 mg/kg +
ibuprofen 5 mg/kg single dose of
each
Primary
1. Temperature at 1 h
Secondary
1. Temperature at 2 h
2. Time spent in department
Hay et al. (43) UK/multi-center-
−35 primary care
sites and
households
156 children aged 6
months to 6 years with
temperature between
37.8◦C and up to 41◦C
axillary
thermometer
Group A: paracetamol 15 mg/kg
every 4–6 h Group B: ibuprofen
10 mg/kg every 6–8 h Group C:
paracetamol + ibuprofen
Primary
1. Min without fever (<37.2◦C) in the
first 4 h
2. Proportion of children normal on
the discomfort scale at 48 h
Secondary
1. Time to fever clearance in the first
24 h
2. Time spent without fever over 24 h
3. Proportion of children without fever
associated symptoms: discomfort,
reduced activity, reduced appetite
and disturbed sleep at 48 h and
day 5
4. Adverse effects
Kramer et al.
(47)
USA/single
center—pediatric
clinic
38 children aged 6
months to 6 years with
temperature > 38◦C
children > 2 years
oral, children < 2
years rectal
thermometer
Group A: paracetamol (15
mg/kg) alternated with placebo
Group B: paracetamol (15
mg/kg) alternating with Ibuprofen
(10 mg/kg)
Primary
1. Temperature at enrolment and
h 3, 4, 5, 6
Secondary
1. Symptom checklist at h 3 and 4
2. Parental perception of efficacy at h
3 and 4
Luo et al. (41) China/single
center—ED and
pediatric
department
474 children aged 6
months to 5 years with
temperature > 38.5C
axillary
thermometer
Group 1: alternating
acetaminophen 10 mg/kg per
dose and ibuprofen 10 mg/kg
per dose (acetaminophen with
shortest interval of 4 h and
ibuprofen with shortest interval of
6 h and the shortest interval
between acetaminophen and
ibuprofen of 2 h) Group 2:
acetaminophen 10 mg/kg per
dose with shortest interval of 4 h
Group 3: ibuprofen 10 mg/kg per
dose with shortest interval of 6 h
Primary
1. NCCPC scores throughout 24 h
2. Mean temperature throughout 24 h
Secondary
1. Proportion of children with
refractory fever for 4 h
2. Low body temperature
3. Antipyretic use
4. Incidence of adverse events
Nabulsi et al.
(45)
Lebanon/multi-
center—pediatric
inpatient services
70 children aged 6
months to 14 years
with temperature >
38.8◦C
rectal thermometer Control: ibuprofen 10 mg/kg
followed by placebo 4 h later
Treatment group: single oral
dose ibuprofen 10 mg/kg
followed by single oral dose
paracetamol 15 mg/kg 4 h later
Primary
1. Proportion of children with
normal body temperature at 6 h
Secondary
1. Proportions of afebrile children at 7
and 8 h
Noori et al.
(42)
Iran/single center –
ED
540 children aged 6
months to 10 years
terwith temperature
between 38◦C and
41◦C
not specified Group 1: acetaminophen 15
mg/kg/dose Group 2: ibuprofen
10 mg/kg/dose Group 3: a
combination of acetaminophen
plus ibuprofen
Primary
1. Temperature at 2–4–6 h
Paul et al. (44) USA/single
center—outpatient
clinics and child
day-care facilities
46 children aged 6
months to 8 years with
temperature > 38.8◦C
temporal artery
thermometer
Group A: single dose ibuprofen
10 mg/kg (oral suspension 100
mg/5mL) Group B: single dose
acetaminophen 15 mg/kg (oral
solution 160 mg/5mL) plus
ibuprofen 10 mg/kg Group C:
ibuprofen 10 mg/kg at the
beginning of the study followed
by 15 mg/kg of acetaminophen
3 h later
Primary
1. Effect of treatment on temperature
over 6 h
(Continued)
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TABLE 2 | Continued
References Country/setting Patients Diagnosis of
fever
Intervention Outcomes
Sarrell et al.
(46)
Central
Israel/multi-
center—primary
pediatric
community
ambulatory
centers
480 children aged 6 to
36 months with
temperature > 38.4◦C
rectal thermometer Group 1: paracetamol 12.5
mg/kg every 6 h Group 2:
ibuprofen 5 mg/kg every 8 h
Group 3: paracetamol 12.5
mg/kg/dose alternating with
ibuprofen 5 mg/kg/dose every
4 h Half of every groups received
initial loading with paracetamol
(25 mg/kg) and the other half
received initial loading with
ibuprofen (10 mg/kg)
Primary
1. Body temperature
2. Stress score
3. Amount of antipyretic used
at the 3 day time point
Secondary
1. Total days that a primary caretaker
had to stay home from work
2. Recurrence of fever (≥37.8◦C)
within 5 and 10 days after initiation
of treatment
3. Number of emergency department
visits within 10 days of enrolment
4. Hepatic and renal function
5. Appearance of gastrointestinal
symptoms or bleeding
Vyas et al.
(36)
India/single
center—pediatric
department
99 children aged 6
months to 12 years
with temperature >
38◦C
tympanometric
thermometer
Group 1: ibuprofen 10 mg/kg
single dose Group 2:
paracetamol 15 mg/kg single
dose Group 3: paracetamol 15
mg/kg + ibuprofen 10 mg/kg
single dose of each
Primary
1. Reduction in temperature at h 4
Secondary
1. Percent reduction of temperature
at h 4
2. Proportion of afebrile children at 1,
2, 3, and 4 h
3. Adverse drug events occurring in
the 4 h period
ED, emergency department, NCCPC, non-communicating children’s pain checklist.
FIGURE 2 | Risk of bias graph.
Alternating Therapy vs. Single Agent
Five studies (41, 44–47) compared alternating therapy with
paracetamol and ibuprofen and single agent therapy. Outcome
measures were: proportion of children remaining febrile at 4 and
6 h from baseline, NCCPC score and doses of medication per
child at one, 2 and 3 days from baseline.
No statistical difference was found in the proportion of
children remaining febrile at 4 h after the initial administration
of therapy (RR 0.33 with 95% CI 0.07–1.43, 511 participants, two
trials). Proportion of children remaining febrile after 6 h from
baseline was lower in the alternating therapy group (RR 0.30 with
95% CI 0.15–0.57, 580 participants, three trials) (Figure 6).
Two studies (41, 46) evaluated NCCPC scores as measure of
child discomfort. Even though Luo et al. (41) found no significant
differences in mean NCCPC scores across groups, pooled data
at day one revealed a statistically significant difference between
alternating and single agent groups, with NCCPC scores being
lower in children receiving alternating therapy than in children
receiving either of the single agents (MD −1.32, 95% CI −2.47
to −0.17, 935 participants, two trials). According to Sarrell
et al. (46), in the alternating therapy group NCCPC scores were
lower also on days 2 (MD −3.76, 95% CI −4.18 to −3.34, 464
participants, one trial) and 3 (MD−3.64, 95% CI−4.08 to−3.20,
464 participants, one trial) (Figure 7).
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FIGURE 3 | Risk of bias summary.
The same two studies (41, 46) evaluated the mean number of
doses of antipyretic per child. No statistical difference was found
between groups in doses of antipyretic per child during the first
24 h (MD −0.44, 95% CI −1.34 to 0.47, 935 participants, two
trials). Sarrell et al. (46) showed that children in the alternating
group required fewer doses of antipyretic during day 2 (MD
−1.39, 95% CI −2.29 to −0.49, 464 participants, one trial) and
day 3 (MD −1.38, 95% CI −1.49 to −1.28, 464 participants, one
trial) (Figure 8).
Adverse Events
Overall, no serious adverse events were observed in any studies.
The reported non-severe adverse events were gastrointestinal
symptoms (mainly nausea, abdominal pain, diarrhea, and
vomiting) (36, 41, 43, 47), mild elevated liver enzymes and
mild abnormal renal function, normalized by 14 day follow-
up (46), skin rash (36, 41, 43), asthma (41). Those events
were distributed similarly between the different comparison
groups (Table 5).
TABLE 3 | Comparison 1: combined therapy vs. single agent.
Outcome or
subgroup
Studies Participants Statistical method Effect estimate
Proportion
remaining febrile
3 RR (M-H, Random,
95% CI)
Subtotals only
Hour 1 2 133 RR (M-H, Random,
95% CI)
0.46 [0.20, 1.07]
Hour 4 3 289 RR (M-H, Random,
95% CI)
0.18 [0.06, 0.53]
Hour 6 1 40 RR (M-H, Random,
95% CI)
0.10 [0.01, 0.71]
Mean
temperature (◦C)
4 MD (IV, Random,
95% CI)
Subtotals only
Hour 1 2 163 MD (IV, Random,
95% CI)
−0.29 [−0.45, −0.13]
Hour 4 3 713 MD (IV, Random,
95% CI)
−0.12 [−0.34, 0.10]
Hour 6 2 580 MD (IV, Random,
95% CI)
−0.04 [−0.13, 0.05]
RR, risk ratio; MD, mean difference.
TABLE 4 | Comparison 2: alternating therapy vs. single agent.
Outcome or
subgroup
Studies Participants Statistical method Effect estimate
Proportion
remaining febrile
3 RR (M-H, Random,
95% CI)
Subtotals only
Hour 4 2 511 RR (M-H, Random,
95% CI)
0.33 [0.07, 1.43]
Hour 6 3 580 RR (M-H, Random,
95% CI)
0.30 [0.15, 0.57]
NCCPC score 2 MD (IV, Random,
95% CI)
−2.57 [−3.36, −1.79]
Day 1 2 935 MD (IV, Random,
95% CI)
−1.32 [−2.47, −0.17]
Day 2 1 464 MD (IV, Random,
95% CI)
−3.76 [−4.18, −3.34]
Day 3 1 464 MD (IV, Random,
95% CI)
−3.64 [−4.08, −3.20]
Doses of
medication per
child
2 MD (IV, Random,
95% CI)
−0.92 [−1.36, −0.48]
Day 1 2 935 MD (IV, Random,
95% CI)
−0.44 [−1.34, 0.47]
Day 2 1 464 MD (IV, Random,
95% CI)
−1.39 [−2.29, −0.49]
Day 3 1 464 MD (IV, Random,
95% CI)
−1.38 [−1.49, −1.28]
RR, risk ratio; MD, mean difference; NCCPC, non-communicating children’s
pain checklist.
Quality of the Evidence
The quality of the evidence was low or very low for
all outcomes except for two subgroups in the comparison
combined therapy vs. single agent (proportion remaining
febrile at 4 h, mean temperature at 1 h), which did not
suffer of significant inconsistency or imprecision (Tables 6, 7;
Supplementary Tables 1, 2).
DISCUSSION
In the present study we updated literature findings regarding the
efficacy and safety of combined/alternating use of antipyretics in
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FIGURE 4 | Comparison: combined vs. single agent, Outcome: proportion remaining febrile.
FIGURE 5 | Comparison: combined vs. single agent, Outcome: mean temperature.
children, 5 years after the publication of the previous Cochrane
review available at this regard (22). Several new additional studies
were available, including one publication exploring the effect
on the child’s discomfort, which represents the main goal of
antipyretic therapy in children. Even if, overall, the results of
our systematic review are aligned with the ones presented in the
previous Cochrane review (22), including the additional studies,
some differences were observed. The main discrepancy concerns
the effect of combined therapy on the mean temperature: while
administering combined paracetamol and ibuprofen therapy to
febrile children resulted in a lower mean temperature at 1 h
after treatment, the mean difference in temperature at 4 and
6 h was no more statistically significant. Moreover, the reduction
in body temperature reached after 1 h was small (0.29◦C).
Although there is no international consensus on the definition
of a clinically relevant reduction in temperature, most authors
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FIGURE 6 | Comparison: alternating vs. single agent, Outcome: proportion remaining febrile.
FIGURE 7 | Comparison: alternating vs. single agent, Outcome: NCCPC score.
considered meaningful only reductions higher than 1◦C. Thus,
a reduction in temperature of 0.29◦C can be considered as not
clinically relevant.
There is, instead, a significant difference in the proportion
of children reaching apyrexia at 4 and 6 h after combined
treatment and at 6 h after alternating treatment, compared
to children treated with monotherapy, consistently to
previous findings (19). These results support the evidence
that giving both paracetamol and ibuprofen, in a combined
or alternating regimen, could be more effective in treating
fever, compared to monotherapy alone. Nevertheless, the
confidence interval of pooled results was wide, with a superior
limit close to one, suggesting a possible imprecision of the
point estimates.
Regarding the NCCPC score, in this review the overall mean
difference among groups was lower than the one reported
in the 2013 Cochrane review, which was based on a single
study. According to Luo et al. (41), indeed, there was no
improvement on the child’s discomfort during the first 24 h with
alternating treatment vs. monotherapy. Moreover, the pooled
mean difference in the number of medications per child used
during the first 24 h was not significantly different.
During the follow-up period, no serious adverse events
were observed. Furthermore, non-severe adverse events were
spread similarly between groups. However, this study has not
the statistical power to detect rare adverse drug reactions.
Additional studies are needed to confirm the safety of combined
or alternating therapy. Indeed, some studies revealed warning
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FIGURE 8 | Comparison: alternating vs. single agent, Outcome: doses of medication per child.
TABLE 5 | Adverse effects.
Studies N Duration of
follow-up
Serious adverse
events
Non-serious adverse events
Erlewyn-Lajeunesse et al. (34) 123 2 h Not reported Not reported
Hay et al. (43) 156 5 days 5 admission to
hospital, reasons
not reported; no
difference
between groups
Paracetamol group: diarrhea, n = 10, vomiting, n = 6, rash, n = 2, cough, n = 2;
ibuprofen group: diarrhea, n = 9, vomiting, n = 3, rash, n = 2; combination group:
diarrhea, n = 12, vomiting, n = 2, rash, n = 1, cough, n = 1
Kramer et al. (47) 38 6 h None observed Diarrhea, flatulence, emesis, decreased appetite, epigastric pain, nausea, headache,
insomnia; n = 8, no difference between groups
Luo et al. (41) 474 24 h None observed Paracetamol group: gastrointestinal symptoms, n = 133, rash, n = 14; ibuprofen
group: gastrointestinal symptoms n=134, rash, n = 13, asthma, n = 2; alternating
group: gastrointestinal symptoms, n = 132, rash, n = 13
Nabulsi et al. (45) 70 8 h None observed None observed
Noori et al. (42) 540 6 h None observed None observed
Paul et al. (44) 46 6 h Not reported Not reported
Sarrell et al. (46) 480 14 days None observed Paracetamol group: mild elevated liver enzymes, n = 4, mild abnormal renal function,
n = 5; ibuprofen group: mild elevated liver enzymes, n = 2, mild abnormal renal
function, n = 4; alternating group: mild elevated liver enzymes, n = 2, mild abnormal
renal function, n = 5; all normalized by 14 day follow up
Vyas et al. (36) 99 4 h None observed Paracetamol group: vomiting, n = 1, abdominal pain, n = 1, (doubtful relationship to
treatment); ibuprofen group: nausea, n = 1, abdominal pain, n = 1, maculopapular
skin rash, n = 1, (possible relationship to treatment); combination group: vomiting, n
= 1 (doubtful relationship to treatment), abdominal pain, n = 2, skin rash, n = 1
(possible relationship to treatment)
signs regarding the safety of combined therapy, focusing on
possible renal injury (48, 49).
Finally, some authors underlined that the
risk of administration errors by the caregivers
could be increased using combined or alternating
therapy (11).
Limitations of the Study
This study shows some limitations. There was significant
heterogeneity between studies, both in the population
sample (age, etiology of fever, comorbidities), both in
the methods used (doses of medications, regimens and
frequency of administration, methods of measuring body
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TABLE 6 | Summary of findings: combined therapy vs. single agent.
Outcomes Anticipated absolute effects* (95% CI) Relative effect (95% CI) N of participants
(studies)
Certainty of the
evidence
(GRADE)Risk with single agent Risk with combined
Proportion remaining
febrile—Hour 1
Study population RR 0.46 (0.20 to 1.07) 133 (2 RCTs) LOW
268 per 1.000 123 per 1.000 (54 to 287)
Proportion remaining
febrile—Hour 4
Study population RR 0.18 (0.06 to 0.53) 289 (3 RCTs) MODERATE
220 per 1.000 40 per 1.000 (13 to 117)
Proportion remaining
febrile—Hour 6
Study population RR 0.10 (0.01 to 0.71) 40 (1 RCT) VERY LOW
500 per 1.000 50 per 1.000 (5 to 355)
Mean temperature
(◦C)—Hour 1
The mean temperature
(◦C)—Hour 1 ranged from
37.6 to 37.98
MD 0.29 lower (0.45 lower
to 0.13 lower)
- 203 (2 RCTs) MODERATE
Mean temperature
(◦C)—Hour 4
The mean temperature
(◦C)—Hour 4 ranged from
36.48 to 37.5
MD 0.12 lower (0.34 lower
to 0.1 higher)
- 892 (3 RCTs) LOW
Mean temperature
(◦C)—Hour 6
The mean temperature
(◦C)—Hour 6 ranged from
36.96 to 38.5
MD 0.04 lower (0.13 lower
to 0.05 higher)
- 759 (2 RCTs) LOW
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI,
Confidence interval; RR, Risk ratio; OR, Odds ratio; RCT Randomized Controlled Trial.
TABLE 7 | Summary of findings: alternating therapy vs. single agent.
Outcomes Anticipated absolute effects* (95% CI) Relative effect (95% CI) N of participants
(studies)
Certainty of the
evidence
(GRADE)Risk with single agent Risk with alternating
Proportion remaining
febrile—Hour 4
Study population RR 0.33 (0.07 to 1.43) 511 (2 RCTs) LOW
245 per 1.000 81 per 1.000 (17 to 350)
Proportion remaining
febrile—Hour 6
Study population RR 0.30 (0.15 to 0.57) 580 (3 RCTs) LOW
185 per 1.000 55 per 1.000 (28 to 105)
NCCPC score—Day 1 NCCPC score—Day 1
ranged from 5.72 to 11.77
MD 1.32 lower (2.47 lower
to 0.17 lower)
- 1246 (2 RCTs) VERY LOW
NCCPC score—Day 2 NCCPC score—Day 2
ranged from 8.83 to 8.87
MD 3.76 lower (4.18 lower
to 3.34 lower)
- 619 (1 RCT) LOW
NCCPC score—Day 3 NCCPC score—Day 3
ranged from 7.66 to 7.96
MD 3.64 lower (4.08 lower
to 3.2 lower)
- 619 (1 RCT) LOW
Doses of medication
per child—Day 1
The mean doses of
medication per child—Day 1
ranged from 2.78 to 4.33
MD 0.44 lower (1.34 lower
to 0.47 higher)
- 1246 (2 RCTs) VERY LOW
Doses of medication
per child—Day 2
The mean doses of
medication per child—Day 2
ranged from 2.92 to 3.84
MD 1.39 lower (2.29 lower
to 0.49 lower)
- 619 (1 RCT) LOW
Doses of medication
per child—Day 3
The mean doses of
medication per child—Day 3
ranged from 2.84 to 2.9
MD 1.38 lower (1.49 lower
to 1.28 lower)
- 619 (1 RCT) LOW
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI,
Confidence interval; RR, Risk ratio; OR. Odds ratio; RCT, Randomized Controlled Trial.
temperature). Due to the small number of trials, we could
not quantify the impact of these variations. Moreover,
the small number of trials did not allow us to build
funnel plots and we could not exclude the possibility of
publication bias. Finally, the quality of the evidence was
generally poor.
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CONCLUSION
According to results from our updated review, combined or
alternating therapy resulted more effective than monotherapy in
reducing body temperature. However, the benefit seems slighter
than those reported in the previous 2013 Cochrane review (22),
and probably not clinically relevant. Similar results were observed
by pooling data from two studies evaluating the effect on the
child’s discomfort and number of doses of medication. To date,
evidences are not enough to encourage combined or alternating
paracetamol and ibuprofen instead of monotherapy to treat
febrile children. Our updated meta-analysis results reinforce the
current recommendations ofmost of the international guidelines,
discouraging this prescription habit.
Further studies are needed, particularly RCT on a large
sample of febrile children randomized into treatment groups
(combined/alternated vs. single agent), in order to reach a clearer
estimate of effects, and large post-marketing surveillance studies,
in order to detect any rare severe adverse drugs reaction.
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